TCTR20210531008
Not yet recruiting
Phase 4
A randomized investigator-blind study evaluating the efficacy and safety of 0.005% trifarotene cream versus 0.05% VAA cream in the treatment of moderate facial acne.
Galderma Thailand0 sites60 target enrollmentMay 31, 2021
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- moderate acne vulgaris patients
- Sponsor
- Galderma Thailand
- Enrollment
- 60
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Male or female, 18\-50 years of age
- •2\.Participants who have been diagnosed with moderate acne at baseline visit
- •3\.Participants must willingly give informed consent.
Exclusion Criteria
- •1\.Participants who have acneiform eruption (e.g., chloracne, drug\-induced acne) or other facial inflammatory skin conditions precluding the acne assessment
- •2\.Participants who have any uncontrolled or severe diseases or any medical or surgical conditions, such as polycystic ovarian syndrome, may interfere with the interpretation or compliance with the protocol
- •3\.Participants who expose to excessive ultraviolet radiation within one month before the baseline visit or plan to expose intense UV during this trial
- •4\.Participants who are unwilling to refrain from use of prohibited medication including topical (such as topical benzoyl peroxide, azelaic acid, or topical antibiotics) and systemic (such as systemic antibiotics, oral antiandrogens, or oral isotretinoin) medications affecting acne conditions during this trial
- •5\.A pregnant woman or nursing or unable to use non\-hormonal birth control
- •6\.Participants who have a history of study drug allergy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in Combinationwith Pegasys and Copegus for 12 or 24 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Na?ve Patients with Chronic Hepatitis C Genotype 1 Virus Infection. - NDChronic Hepatitis C (CHC) Genotype 1MedDRA version: 12.0Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2009-009608-38-ITF.Hoffmann-La Roche300
Active, not recruiting
Phase 1
A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Copegus for 12 or 24 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus InfectioEUCTR2009-009608-38-FRF.Hoffmann-La Roche300
Active, not recruiting
Not Applicable
A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Copegus for 12 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus InfectioEUCTR2009-009608-38-ATF.Hoffmann-La Roche300
Active, not recruiting
Not Applicable
A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Copegus for 12 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus InfectioChronic Hepatitis C Genotype 1 Virus Infection (Treatment-Naive Patients)MedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2009-009608-38-DEF.Hoffmann-La Roche300
Terminated
Phase 4
A randomized, double-blinded study investigating the safety and efficacy of daily low-dose oral fluconazole versus weekly fluconazole in the treatment of chronic vulvovaginal candidiasisChronic vulvovaginal candidiasisSkin - Dermatological conditionsInfection - Other infectious diseasesRenal and Urogenital - Other renal and urogenital disordersACTRN12614001258640Royal North Shore Hospital200